Work

675 - Dupilumab demonstrates higher likelihood of achieving improvements in signs, symptoms, and quality of life vs lebrikizumab: results from a placebo-adjusted indirect comparison analysis

Year: 2024

Type: article

Source: British Journal of Dermatology

DOI: 10.1093/bjd/ljae266.049

Authors: Patricia Guyot, Yingxin Xu, Amy Praestgaard, Nick Freemantle, Ana B Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian

Institutions: Sanofi (France), Regeneron (United States), University College London, Sanofi (Germany)

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401435965

FWCI: 0.338

Cites:

Cited by: 1

Related to: 10